CAC
RVPHW

Cowen and Company’s Reviva Pharmaceuticals Warrants RVPHW Stock Holding History

Cowen and Company’s Portfolio RVPHW Stock Details RVPHW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-57,100
Closed -$5K – 467
2020
Q1 		$5K Sell
57,100
-51,500
-47% -$7.71K ﹤0.01% 370
2019
Q4 		$27K Buy
108,600
+88,600
+443% +$20.3K ﹤0.01% 350
2019
Q3 		$5K Buy
+20,000
New +$3.83K ﹤0.01% 423

Other funds holding RVPHW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Cowen and Company's RVPHW Position: Q2 2020 in Review

Cowen and Company sold out of Reviva Pharmaceuticals Warrants (RVPHW) in Q2 2020, closing a stake of 57,100 shares — an estimated $5K sold.

Cowen and Company first reported a position in RVPHW in Q3 2019 and held it in 3 quarters. The position peaked at $27K in Q4 2019. 17 funds tracked by Wall St. Rank hold RVPHW as of Q2 2020.

  • Cowen and Company reported no remaining Reviva Pharmaceuticals Warrants position as of Q2 2020 after selling out during the quarter.
  • Cowen and Company sold 57,100 Reviva Pharmaceuticals Warrants shares in Q2 2020, an estimated $5K.
  • Cowen and Company first reported a position in Reviva Pharmaceuticals Warrants in Q3 2019 and held it in 3 quarters.
  • Cowen and Company's Reviva Pharmaceuticals Warrants position peaked at $27K in Q4 2019.
  • 17 funds tracked by Wall St. Rank held Reviva Pharmaceuticals Warrants as of Q2 2020.

Based on Cowen and Company's 13F filing for Q2 2020, filed 13 Aug 2020.